Foundation Medicine
Foundation Medicine is transforming cancer care by providing patients, physicians, and researchers with a deep understanding of the genomic mutations that drive cancer. They offer comprehensive genomic profiling tests and services, support therapy development, and provide educational resources to advance precision medicine. The company actively participates in global, national, and local oncology meetings, collaborates with research institutions, and publishes scientific research to improve cancer diagnostics and treatment. They are committed to inclusive research, fostering an environment of innovation, and ensuring equitable access to their tests through broad coverage and financial assistance programs.
Industries
Nr. of Employees
large (251-1000)
Foundation Medicine
Boston, Massachusetts, United States
Patents
Products
Tissue-based comprehensive genomic profiling (FDA-authorized companion diagnostic)
Clinical NGS assay performed on FFPE tissue to analyze large gene panels and genomic signatures to inform targeted therapy selection, immunotherapy eligibility, and clinical trial matching for advanced solid tumors.
Plasma-based comprehensive genomic profiling (liquid biopsy, regulatory-authorized)
cfDNA-based NGS assay performed on blood to detect genomic alterations across extended gene panels for non-invasive tumor profiling, monitoring, and complementary testing when tissue is unavailable.
DNA and RNA-based genomic profiling for hematologic malignancies
Combined DNA and RNA sequencing assay for hematologic malignancies and fusion detection, applicable to blood, bone marrow, or tissue specimens to support clinical and research use cases.
FoundationOne®CDx (F1CDx)
A qualitative next-generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens.
FoundationOne RNA
A next generation sequencing (NGS) based assay for detection of gene fusions and rearrangements in a broad multigene panel using RNA isolated from formalin-fixed paraffin embedded (FFPE) solid tumor specimens. Provides tumor mutation profiling information for oncology use by qualified healthcare professionals.
FoundationOne RNA laboratory-developed test (LDT)
A comprehensive genomic profiling test to identify cancer-related gene rearrangements in solid tumors, complementing DNA profiling by FoundationOne®CDx. It includes 318 genes known to be somatically altered as rearrangements/fusions in human solid tumors and/or hematologic malignancies, with clinical reporting for 50 RNA rearrangement genes and gene expression profiling of 1212 genes for research use only.
Tissue-based comprehensive genomic profiling (FDA-authorized companion diagnostic)
Clinical NGS assay performed on FFPE tissue to analyze large gene panels and genomic signatures to inform targeted therapy selection, immunotherapy eligibility, and clinical trial matching for advanced solid tumors.
Plasma-based comprehensive genomic profiling (liquid biopsy, regulatory-authorized)
cfDNA-based NGS assay performed on blood to detect genomic alterations across extended gene panels for non-invasive tumor profiling, monitoring, and complementary testing when tissue is unavailable.
DNA and RNA-based genomic profiling for hematologic malignancies
Combined DNA and RNA sequencing assay for hematologic malignancies and fusion detection, applicable to blood, bone marrow, or tissue specimens to support clinical and research use cases.
FoundationOne®CDx (F1CDx)
A qualitative next-generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens.
FoundationOne RNA
A next generation sequencing (NGS) based assay for detection of gene fusions and rearrangements in a broad multigene panel using RNA isolated from formalin-fixed paraffin embedded (FFPE) solid tumor specimens. Provides tumor mutation profiling information for oncology use by qualified healthcare professionals.
FoundationOne RNA laboratory-developed test (LDT)
A comprehensive genomic profiling test to identify cancer-related gene rearrangements in solid tumors, complementing DNA profiling by FoundationOne®CDx. It includes 318 genes known to be somatically altered as rearrangements/fusions in human solid tumors and/or hematologic malignancies, with clinical reporting for 50 RNA rearrangement genes and gene expression profiling of 1212 genes for research use only.
Services
Collaborative projects offering translational assay support, clinical development and companion diagnostic strategy, and commercialization planning for biopharma partners.
Provider-facing decision support services and educational resources to interpret genomic reports and guide treatment planning.
Technical integration of laboratory reports and structured genomic data into electronic medical records and clinical workflows to support automated delivery.
On-demand webinars, guides, and live events focused on genomic profiling, liquid biopsy, biomarker interpretation, and related topics for healthcare professionals.
On-site research lab capabilities and flexible workflows to support assay development, translational experiments, and partner-specific testing.
Collaborative projects offering translational assay support, clinical development and companion diagnostic strategy, and commercialization planning for biopharma partners.
Provider-facing decision support services and educational resources to interpret genomic reports and guide treatment planning.
Technical integration of laboratory reports and structured genomic data into electronic medical records and clinical workflows to support automated delivery.
On-demand webinars, guides, and live events focused on genomic profiling, liquid biopsy, biomarker interpretation, and related topics for healthcare professionals.
On-site research lab capabilities and flexible workflows to support assay development, translational experiments, and partner-specific testing.
Expertise Areas
- Comprehensive genomic profiling for solid tumors
- Liquid biopsy and circulating tumor DNA analysis
- DNA+RNA sequencing for fusion and structural variant detection
- Biomarker signature discovery and clinical validation
Key Technologies
- Next-generation sequencing (NGS)
- Plasma cell-free DNA (cfDNA) sequencing
- RNA sequencing for fusion detection
- ctDNA tumor fraction analytics